{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:02:13Z","timestamp":1789603333758,"version":"build-2803163510"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Zentralbl Chir"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Glucagon-like-Peptide-1-Rezeptoragonisten (GLP-1-RA) haben sich innerhalb weniger\n\t\t\tJahre von einer Antidiabetika-Klasse zu einer der einflussreichsten pharmakologischen\n\t\t\tSubstanzgruppen der Inneren Medizin entwickelt. Die zugelassenen Wirkstoffe Semaglutid,\n\t\t\tLiraglutid und der duale GIP\/GLP-1-Agonist Tirzepatid erreichen Gewichtsreduktionen von\n\t\t\tbis zu 22% des K\u00f6rpergewichts. Die enge pathophysiologische Verflechtung zwischen\n\t\t\tAdipositas, metabolischem Syndrom und urologisch-andrologischen Erkrankungen f\u00fchrt zu\n\t\t\teiner wachsenden klinischen Relevanz dieser Substanzen auch f\u00fcr die Urologie.Die\n\t\t\tvorliegende \u00dcbersichtsarbeit fasst die Ergebnisse einer systematischen PubMed-Recherche\n\t\t\t(2020\u20132026) zu erektiler Dysfunktion, Hypogonadismus, m\u00e4nnlicher Fertilit\u00e4t,\n\t\t\tNephroprotektion, Prostatakarzinom, Harntraktsymptomen und perioperativen Risiken unter\n\t\t\tGLP-1-RA-Therapie zusammen.Die GLP-1-RA zeigen in mehreren urologisch relevanten\n\t\t\tBereichen klinisch bedeutsame Effekte: Anstieg des Gesamttestosterons und Verbesserung\n\t\t\tder erektilen Funktion bei M\u00e4nnern mit Adipositas und metabolischem Hypogonadismus,\n\t\t\tnephroprotektive Wirkung mit Reduktion der Albuminurie und Verlangsamung der\n\t\t\teGFR-Progression, Hinweise auf reduziertes Prostatakarzinomrisiko in epidemiologischen\n\t\t\tStudien sowie indirekter Nutzen bei Belastungsinkontinenz und \u00fcberaktiver Blase \u00fcber die\n\t\t\tGewichtsreduktion. Gleichzeitig bestehen klinisch relevante Warnsignale: ein 4,5-fach\n\t\t\terh\u00f6htes ED-Risiko (ED: erektile Dysfunktion) bei nicht diabetischen M\u00e4nnern unter\n\t\t\tSemaglutid in einer gro\u00dfen Datenbankanalyse, neuartige urologische Nebenwirkungen in\n\t\t\tFallberichten, perioperatives Aspirationsrisiko durch verz\u00f6gerte Magenentleerung sowie\n\t\t\teine nahezu vollst\u00e4ndige Datenl\u00fccke bei Frauen.Die GLP-1-RA sind f\u00fcr den Urologen\n\t\t\tsowohl therapeutische Chance als auch klinische Herausforderung. Eine systematische\n\t\t\tandrologisch-nephrologische Begleitung sowie eine aktive Aufkl\u00e4rung \u00fcber urogenitale und\n\t\t\tperioperative Implikationen sind empfehlenswert. Prospektive kontrollierte Studien mit\n\t\t\tprim\u00e4r urologischen Endpunkten sind sinnvoll.<\/jats:p>","DOI":"10.1055\/a-2943-1080","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:11:50Z","timestamp":1789600310000},"source":"Crossref","is-referenced-by-count":0,"title":["GLP-1-Rezeptoragonisten in der Urologie und Andrologie: Indikationen, Chancen und klinisch relevante Nebenwirkungen"],"prefix":"10.1055","author":[{"given":"Theodor","family":"Klotz","sequence":"additional","affiliation":[{"name":"Urologiezentrum Schwandorf, Deutschland","place":["Schwandorf"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic\n\t\t\t\t\treview and network meta-analysis of randomised controlled trials","volume":"403","author":"Q Shi","year":"2024","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/medicina60010050","article-title":"Impact of GLP-1 Agonists on Male Reproductive Health \u2013 A Narrative\n\t\t\t\t\tReview","volume":"60","author":"AA Varnum","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3390\/cancers17091576","article-title":"May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer\n\t\t\t\t\tAggressiveness and Progression?","volume":"17","author":"J Drewa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/andr.70022","article-title":"Effects of glucagon-like peptide 1 receptor agonists on testicular\n\t\t\t\t\tdysfunction: A systematic review and meta-analysis","volume":"13","author":"G Salvio","year":"2025","journal-title":"Andrology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/andr.70238","article-title":"Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and\n\t\t\t\t\tSodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors:\n\t\t\t\t\tSystematic Review and Meta-Analysis","author":"G Corona","year":"2026","journal-title":"Andrology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/andr.13519","article-title":"Long-acting glucagon-like peptide 1 receptor agonists boost erectile\n\t\t\t\t\tfunction in men with type 2 diabetes mellitus complaining of erectile\n\t\t\t\t\tdysfunction: A retrospective cohort study","volume":"12","author":"G Lisco","year":"2024","journal-title":"Andrology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41443-024-00895-6","article-title":"Prescribing semaglutide for weight loss in non-diabetic, obese patients is\n\t\t\t\t\tassociated with an increased risk of erectile dysfunction: a TriNetX database\n\t\t\t\t\tstudy","volume":"37","author":"C Able","year":"2025","journal-title":"Int J Impot Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1496416","article-title":"Potential impact of GLP-1 receptor agonists on male fertility: a fable of\n\t\t\t\t\tcaution","volume":"15","author":"SS Du Plessis","year":"2024","journal-title":"Front Physiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2\n\t\t\t\t\tDiabetes","volume":"391","author":"V Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular\n\t\t\t\t\tdisease in the SELECT trial","volume":"30","author":"HM Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.1111\/dom.70054","article-title":"Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults\n\t\t\t\t\twith obesity: A target trial emulation study","volume":"27","author":"H Tang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A\n\t\t\t\t\tSystematic Review and Meta-Analysis","volume":"110","author":"SA Lee","year":"2026","journal-title":"Transplantation"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/toxins17110542","article-title":"Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is\n\t\t\t\t\tAssociated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA\n\t\t\t\t\tTreatment in Non-Diabetic Adults with Overactive Bladder","volume":"17","author":"MAM Hammad","year":"2025","journal-title":"Toxins (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa0806375","article-title":"Weight Loss to Treat Urinary Incontinence in Overweight and Obese\n\t\t\t\t\tWomen","volume":"360","author":"LL Subak","year":"2009","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ejendo\/lvag033","article-title":"GLP-1 receptor agonist treatment in women with polycystic ovary syndrome \u2013\n\t\t\t\t\ta systematic review and meta-analysis","volume":"194","author":"M Forslund","year":"2026","journal-title":"Eur J Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/sxmrev\/qeaf074","article-title":"Beyond metabolism: sexual dysfunction and weight-loss drugs","volume":"14","author":"JM Fuentes-Mendoza","year":"2026","journal-title":"Sex Med Rev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cancers17010078","article-title":"Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity:\n\t\t\t\t\tA Nationwide Analysis of 1.1 Million Patients","volume":"17","author":"S Levy","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2026.103368","article-title":"Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the\n\t\t\t\t\turological health","volume":"65","author":"A Tariq","year":"2026","journal-title":"Urol Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12958-025-01425-9","article-title":"Short-term impact of tirzepatide on metabolic hypogonadism and body\n\t\t\t\t\tcomposition in patients with obesity: a controlled pilot study","volume":"23","author":"S La Vignera","year":"2025","journal-title":"Reprod Biol Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of\n\t\t\t\t\tObesity","volume":"387","author":"AM Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/biom15091284","article-title":"The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile\n\t\t\t\t\tFunction: Friend or Foe?","volume":"15","author":"D Kounatidis","year":"2025","journal-title":"Biomolecules"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3390\/jcm10173955","article-title":"GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to\n\t\t\t\t\tClinical Outcomes","volume":"10","author":"A Rojano Toimil","year":"2021","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2337\/dc25-1080","article-title":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2\n\t\t\t\t\tDiabetes: Results From the SOUL Randomized Trial","volume":"49","author":"JFE Mann","year":"2026","journal-title":"Diabetes Care"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/cancers16081538","article-title":"From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor\n\t\t\t\t\tAgonist\u2019s Dual Role in Prostate Cancer","volume":"16","author":"A Alhajahjeh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clnu.2025.10.006","article-title":"Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers\n\t\t\t\t\tin diabetes: A systematic review and meta-analysis","volume":"55","author":"W Chen","year":"2025","journal-title":"Clin Nutr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the\n\t\t\t\t\tSURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"M Look","year":"2025","journal-title":"Diabetes Obes Metab"}],"container-title":["Zentralblatt f\u00fcr Chirurgie - Zeitschrift f\u00fcr Allgemeine, Viszeral-, Thorax- und Gef\u00e4\u00dfchirurgie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2943-1080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:11:51Z","timestamp":1789600311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2943-1080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1055\/a-2943-1080","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-409X","1438-9592"],"issn-type":[{"value":"0044-409X","type":"print"},{"value":"1438-9592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}